Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
Clin Ther
; 32(4): 744-57, 2010 Apr.
Article
en En
| MEDLINE
| ID: mdl-20435244
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Testosterona
/
Leuprolida
/
Antineoplásicos Hormonales
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Ther
Año:
2010
Tipo del documento:
Article
País de afiliación:
Austria